Browse EX-10 agreements

March 13, 2026

Andrew J. McLean

c/o Lands’ End, Inc.

5 Lands’ End Lane

Dodgeville, WI 53595

 

Re: Success Bonus

Dear Andrew:

As you know, in March 2025 Lands’ End, Inc. (the “Company”) announced that it was exploring strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value. That process culminated with the announcement on January 26, 2026 of the transaction with WHP Global (the “Transaction”).

In recognition of your efforts toward completing the Transaction, and because retention of key employees of the Company is an essential consideration for us following this process, we are providing you with the opportunity to earn the payments described in this letter (this “Letter”), in the total amount of $2,200,000.

…

March 13, 2026

Bernard McCracken

c/o Lands’ End, Inc.

5 Lands’ End Lane

Dodgeville, WI 53595

 

Re: Success Bonus

Dear Bernie:

As you know, in March 2025 Lands’ End, Inc. (the “Company”) announced that it was exploring strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value. That process culminated with the announcement on January 26, 2026 of the transaction with WHP Global (the “Transaction”).

In recognition of your efforts toward completing the Transaction, and because retention of key employees of the Company is an essential consideration for us following this process, we are providing you with the opportunity to earn the payments described in this letter (this “Letter”), in the total amount of $787,500.

…

March 13, 2026

Peter L. Gray

c/o Lands’ End, Inc.

5 Lands’ End Lane

Dodgeville, WI 53595

 

Re: Success Bonus

Dear Peter:

As you know, in March 2025 Lands’ End, Inc. (the “Company”) announced that it was exploring strategic alternatives, including a sale, merger or similar transaction involving the Company, to maximize shareholder value. That process culminated with the announcement on January 26, 2026 of the transaction with WHP Global (the “Transaction”).

In recognition of your efforts toward completing the Transaction, and because retention of key employees of the Company is an essential consideration for us following this process, we are providing you with the opportunity to earn the payments described in this letter (this “Letter”), in the total amount of $1,042,875.

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

PLATFORM OPTION AGREEMENT

THIS PLATFORM OPTION AGREEMENT (“Agreement”) is entered into and effective as of October 16, 2025 (the “Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parasa Holding LLC, a Delaware limited liability company (“Parasa”), and Korsana Biosciences, Inc., a Delaware corporation (“Korsana”). Paragon, Parasa and Korsana are also referred to herein individually as a “Party”, or collectively as the “Parties.”

RECITALS

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

BIOLOGICS MASTER SERVICES AGREEMENT

This Biologics Master Services Agreement (this “Agreement”) is dated and effective as of December 12, 2024 (the “Effective Date”) and is between KORSA Biosciences, Inc., a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Client”) and WuXi Biologics (Hong Kong) Limited, with its registered address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“Provider”), each of Client and Provider being a “Party,” and collectively the “Parties.”

 

A.

Client discovers and develops biologics.

 

B.

Provider coordinates the biologics development and manufacturing services, including those provided by certain affiliated operating companies.

 

C.

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT

THIS AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT (“Amendment”), effective as of March 2, 2026 (the “Amendment Effective Date”), is entered into and made by and between WuXi Biologics Ireland Limited, having an address at Dundalk Science & Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (“WuXi Biologics”), and Korsana Biosciences, Inc., having its principal place of business at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

ANTIBODY DISCOVERY AND OPTION AGREEMENT

THIS ANTIBODY DISCOVERY AND OPTION AGREEMENT (“Agreement”) is entered into and effective as of September 5, 2025 (the “Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parasa Holding LLC, a Delaware limited liability company (“Parasa”) and Korsa Biosciences, Inc., a Delaware corporation (“Korsa”). Paragon, Parasa and Korsa are also referred to herein individually as a “Party”, or collectively as the “Parties.”

RECITALS

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

CELL LINE LICENSE AGREEMENT

This Cell Line License Agreement (“Agreement”), effective as of December 2, 2024 (“EFFECTIVE DATE”), is entered and made by and between WuXi Biologics Ireland Limited, having an address at Dundalk Science & Technology Park, Mullagharlin, Dundalk, Co Louth A91 X56F, Ireland (collectively, “WuXi Biologics”) and KORSA Biosciences, Inc. a Delaware corporation, with an office at 221 Crescent Street, Building 23, Suite 105, Waltham, MA 02453 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”

The Parties agree as follows:

 

1.

Definitions

 

 

1.1

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL.

 

 

 

To:

Korsana Biosciences, Inc.

221 Crescent Street, Building 23, Suite 105

Waltham, MA 02453

Attn: Jonathan Violin, CEO

 

 

RE:

AOC Research Letter Agreement

April 3, 2026

Dear Jonathan,

…

PERFORMANCE STOCK UNIT GRANT NOTICE

 

Skillsoft Corp., a Delaware corporation (the “Company”), pursuant to its 2020 Omnibus Incentive Plan, as it may be amended and restated from time to time (the “Plan”), hereby grants to the Participant set forth below the number of Performance Stock Units set forth below (the “PSUs”). The PSUs are subject to all of the terms and conditions as set forth in this Performance Stock Unit Grant Notice (this “Grant Notice”), in the Performance Stock Unit Agreement (attached hereto), and in the Plan, all of which are incorporated herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Plan.

 

Participant: [*]

 

Date of Grant: [*]

 

Performance Period: [*]

 

Vesting Commencement Date: [*]

 

Target Number of Performance Stock Units: [*]

…

Privileged and Confidential

Subject to the Company’s Talent and Compensation Committee’s Approval

 

Corporate Office: 300 Innovative Way, Suite 201

Nashua, NH 03062 USA

skillsoft.com

O: +1-603-324-3000

 

 

May 20, 2026

 

John Frederick Via email

 

Dear John:

 

The purpose of this letter agreement (this “Agreement”) is to confirm the terms of the remainder of your employment with Skillsoft Corp. (the “Company”) and your retirement from the Company. Capitalized terms not defined herein shall have the respective meanings ascribed to them in the Offer Letter between you and the Company dated as of May 15, 2025 (the “Offer Letter”).

 

1.           Transition Period and Retirement Date.

…

June 1, 2026

 

 

Scott Semel

Via Email

 

Dear Scott,

 

Per the terms of your offer letter with Skillsoft Corp. (the “Company”) dated November 17, 2025 (the “Offer Letter”), your employment may be extended beyond the Initial Term (as defined in the Offer Letter) by mutual agreement. This letter serves to acknowledge the extension of your employment term with the Company for an additional three months, from May 16, 2026 through August 16, 2026, inclusive (the “Extended Term”).

…